Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis

SAN DIEGO–(BUSINESS WIRE)–#ALS—Neuropore Therapies, Inc. announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34. NPT520-34 is a small molecule being developed for Parkinson’s disease and amyotrophic lateral sclerosis. The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.

Doug Bonhaus, CEO & CSO of Neuropore, stated, “We are excited to complete the Phase 1 clinical trial with NPT520-34. We believe NPT520-34 represents a promising new small molecule therapeutic opportunity for patients living with Parkinson’s disease and amyotrophic lateral sclerosis. NPT520-34 proved to be safe and tolerable at all doses tested, including those believed to be therapeutically relevant. The results of this study support moving forward to a safety study in patients. Our team is currently evaluating the optimal study design and patient population for the next study.”

About Parkinson’s disease

Parkinson’s disease (PD) is a debilitating neurodegenerative disorder afflicting an estimated seven to ten million patients worldwide. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa or dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs become less effective at treating the symptoms.

About Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a devastating progressive neurological disease for which there is no cure. A little over 5,000 people in the U.S. are diagnosed with ALS each year with an estimated 16,000 Americans suffering with the disease at any given time. Only 10% of ALS patients survive longer than 10 years.

About NPT520-34

NPT520-34 is a clinical stage orally bioavailable small molecule that reduces astrocytic and microglial markers of neuroinflammation with robust beneficial effects on neuropathology and motor function in animal models of Parkinson’s disease. NPT520-34 also has been shown to reduce the expression of markers of neuroinflammation and neuropathology in animal models of amyotrophic lateral sclerosis and Alzheimer’s disease.

About Neuropore Therapies, Inc.

Neuropore Therapies Inc. is a San Diego, California-based biopharmaceutical company developing novel disease modifying small molecule therapeutics for the treatment of neurodegenerative disorders. Neuropore’s therapeutic candidates block the neurotoxic oligomeric aggregates of misfolded proteins which are the primary drivers of disease pathology by preventing the induction of damaging neuroinflammation mechanisms common to many neurodegenerative disorders. By targeting the underlying mechanisms by which neuroinflammation drives a vicious cycle of protein pathology and neurodegeneration, Neuropore’s therapeutic candidates may have broad applications in slowing disease progression and improving symptoms across a wide range of neuro-inflammatory / neuro-degenerative disorders.

For more information visit www.neuropore.com.

Contacts

Douglas W. Bonhaus, Ph.D.

Chief Executive Officer & Chief Science Officer

T +1 858-273-1831

[email protected]